Pharmaceutical Business Review
Anonymous User | Login

Arch Chemicals Q3 Profit Declines

Published: 04-Nov-2009

Higher pricing and the benefit from the Advantis acquisition were more than offset by lower volumes and unfavorable foreign exchange

Arch Chemicals has reported sales of $350.5m for the third quarter of 2009, compared to $367.9m for the same period of 2008. Higher pricing and the benefit from the Advantis acquisition were more than offset by lower volumes and unfavorable foreign exchange.

Third-quarter profit fell to $10.3m, or 39% on a prior-year trade-related gain while demand remained weak for its industrial biocides, though earnings beat expectations.

Treatment products reported sales of $309.7m and operating income of $25.2m in 2009 compared with sales of $310.9m and operating income of $31.2m in 2008.

Personal care and industrial biocides reported sales of $77.8m and operating income of $13.6m compared to sales and operating income of $78.8m and $12.3m, respectively, in 2008. Operating income increased $1.3m as higher pricing and favorable foreign exchange were partially offset by lower volumes and higher plant costs related to the new manufacturing facilities in China.

Michael Campbell, chairman, president and CEO of Arch Chemicals, said: “I am pleased by our strong third quarter results. We realised increased selling prices in several of our businesses and saw higher demand for our health and hygiene biocides. We also benefited from significant cost reduction efforts across all businesses, which mitigated continuing unfavorable sales comparisons across most of our businesses and the protracted impact of unfavorable weather patterns in our North American HTH water products business.

“We remain on target to achieve our earnings forecast. While end-use demand for our products appears to have stabilized, we are not yet experiencing a marked recovery in demand. Our results are benefiting from numerous supply chain, manufacturing and SG&A cost-reduction initiatives across all of our businesses.

“Our relentless commitment to improve operating margins by raising prices wherever possible, aggressively reducing costs, optimising our portfolio and maximising cash generation will sustain Arch through these challenging times, and is the driver of our long-term profitable growth.”

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ADAPT Localization

The Translation and Localization Specialists ...

Adis

Independently Evaluated Drug Information ...

Almac

Drug Development Solutions ...

Altiora

To Strive for the Highest ...

Anoto

Providing Unique Technology for Digital Pen and Paper ...

Aptuit

Drug Discovery and Development ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

CaseBase Management

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

SafetyBase Interchange

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

ClinicalBase Trial

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

Reliable Prediction of White Plasma Levels

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Kinetics and Metabolism

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Drug Safety Evaluation

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Related Companies

No items to display

Suppliers Product News

Almac Completes Phase One of Its Expansion Plan to Pharma Services Facilities

New $15m facility will "meet growing business need for its integrated product development and commercial services."

Organisations Throwing Mobile Technology at Problems With Little Consideration of Actual User and Business Needs, Quocirca

Survey reveals detrimental impact on organisational effectiveness and IT expenditure in healthcare and finance across the UK, France, Germany and the US.

Digital Pen and Paper Technology Helps Accelerate Clinical Trials

Digital pen and paper technology captures handwritten clinical data electronically, quickly and securely to save time and cost in drug discovery process.

Aptuit Outlines 2010 Business Priorities at 28th Annual J.P. Morgan Healthcare Conference

Aptuit, Inc., a contract development and manufacturing company, today will provide an update on 2010 business priorities and discuss its integrated service offerings at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

Aptuit Publishes Study which Demonstrates the Value of Early Insights into the Characterisation of Drug Compounds

New research on the solid-state characterisation of finasteride clearly outlines a systematic approach to characterising and monitoring active pharmaceutical ingredients

Aptuit Launches Program to Accelerate Early Stage Drug Development

Aptuit INDiGO™ accelerates drug development from pre-clinical candidate selection to regulatory filing on a fixed timeline and price

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address